Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
-

Ratings ESG MSCI

Ratings TAUNS Laboratories,Inc.: Strengths and Weaknesses

Highlights: TAUNS Laboratories,Inc.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • With a P/E ratio at 10.14 for the current year and 14.93 for next year, earnings multiples are highly attractive compared with competitors.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: TAUNS Laboratories,Inc.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Rating Financials

TAUNS Laboratories,Inc. SectorJapan

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

-

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

TAUNS Laboratories,Inc. SectorJapan

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

-
More ratings

Rating Consensus

TAUNS Laboratories,Inc. SectorJapan

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

TAUNS Laboratories,Inc. SectorJapan

Visibility

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

TAUNS Laboratories,Inc. SectorJapan

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
345M -
21.66B -
AAA
- -
10.16B
A
8.16B -
BB
- -
7.08B -
6.59B
AA
-
6.03B
BBB
4.33B
BBB
4.22B - - - - - - -
2.81B
CCC
-
Average 7.14B
A
Weighted average by Cap.
A
  1. Stock Market
  2. Stocks
  3. 197A Stock
  4. Ratings TAUNS Laboratories,Inc.